Evidence map›Paper›PMID 27875297›Full record

ArticleThe Journal of biological chemistry2016

Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.

Carly A Baehr, Catherine J Huntoon, Song-My Hoang, Calvin R Jerde, Larry M Karnitz

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Uracil-DNA Glycosylase fromInternational journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Noncatalytic Domains in DNA Glycosylases.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Carly A BaehrFrom the Departments of Molecular Pharmacology and Experimental Therapeutics and.
Catherine J HuntoonFrom the Departments of Molecular Pharmacology and Experimental Therapeutics and.
Song-My HoangFrom the Departments of Molecular Pharmacology and Experimental Therapeutics and.
Calvin R JerdeFrom the Departments of Molecular Pharmacology and Experimental Therapeutics and.
Larry M KarnitzFrom the Departments of Molecular Pharmacology and Experimental Therapeutics and karnitz.larry@mayo.edu.
Mayo Clinic · USRadiation Oncology Associates · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Predoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4M
NCI NIH HHS P50 CA136393NIGMS NIH HHS T32 GM072474
6 · The paper itself

Abstract

Uracil N-glycosylase 2 (UNG2), the nuclear isoform of UNG, catalyzes the removal of uracil or 5-fluorouracil lesions that accumulate in DNA following treatment with the anticancer agents 5-fluorouracil and 5-fluorodeoxyuridine (floxuridine), a 5-fluorouracil metabolite. By repairing these DNA lesions before they can cause cell death, UNG2 promotes cancer cell survival and is therefore critically involved in tumor resistance to these agents. However, the mechanisms by which UNG2 is regulated remain unclear. Several phosphorylation sites within the N-terminal regulatory domain of UNG2 have been identified, although the effects of these modifications on UNG2 function have not been fully explored, nor have the identities of the kinases involved been determined. Here we show that glycogen synthase kinase 3 (GSK-3) interacts with and phosphorylates UNG2 at Thr

Indexed as

Antimetabolites, AntineoplasticCell NucleusCell SurvivalDNA GlycosylasesDNA RepairDNA ReplicationFemaleFloxuridineFluorouracilGlycogen Synthase Kinase 3HumansOvarian NeoplasmsPhosphorylationTumor Cells, CulturedAntimetabolites, AntineoplasticCCNO protein, humanDNA GlycosylasesFloxuridineFluorouracilGlycogen Synthase Kinase 3anticancer drugbase excision repair (BER)DNA glycosylaseDNA repairfloxuridineglycogen synthase kinase 3 (GSK-3)phosphorylationserine/threonine protein kinaseuracil N-glycosylase 2 (UNG2)

Identifiers

PMID27875297
PMCPMC5207193
OpenAlexW2556010928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.